Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
Oncotarget|September 3, 2016
An oncogenic role for sphingosine kinase 2Heidi A Neubauer, Duyen H Pham, Julia R Zebol, et al.Pharmaceuticals (Basel, Switzerland)|November 10, 2022
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell LymphomaHarsimran Kaur Garcha, Nabanita Nawar, Helena Sorger, et al.Leukemia|April 15, 2025
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemiaAnnika Dechow, Sanna Timonen, Aleksandr Ianevski, et al.Cancers|April 25, 2020
STAT5 is Expressed in CD34<sup>+</sup>/CD38<sup>-</sup> Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative NeoplasmsEmir Hadzijusufovic, Alexandra Keller, Daniela Berger, et al.Molecular Cancer|March 31, 2022
KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasisTanja Limberger, Michaela Schlederer, Karolina Trachtová, et al.Cancer Research|October 30, 2025
Multi-omics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic DiscoveryAleksandr Ianevski, Kristen Nader, Julia Nguyen, et al.Nature Communications|June 9, 2019
Structural and functional consequences of the STAT5B<sup>N642H</sup> driver mutationElvin D de Araujo, Fettah Erdogan, Heidi A Neubauer, et al.Journal of Medicinal Chemistry|June 8, 2021
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic LeukemiaKrimo Toutah, Nabanita Nawar, Sanna Timonen, et al.Hemasphere|December 2, 2024
Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphomaDaniel Pölöske, Helena Sorger, Anna Schönbichler, et al.Molecular Cancer|November 1, 2024
Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironmentChristina Sternberg, Martin Raigel, Tanja Limberger, et al.Pageof 4